Akebia Therapeutics (AKBA) Short Interest Ratio & Short Volume → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free AKBA Stock Alerts $1.37 +0.01 (+0.74%) (As of 04:28 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Akebia Therapeutics Short Interest DataCurrent Short Volume13,400,000 sharesPrevious Short Volume10,130,000 sharesChange Vs. Previous Month+32.28%Dollar Volume Sold Short$24.52 millionShort Interest Ratio / Days to Cover3.0Last Record DateMarch 31, 2024Outstanding Shares209,370,000 sharesPercentage of Shares Shorted6.40%Today's Trading Volume2,081,815 sharesAverage Trading Volume4,320,985 sharesToday's Volume Vs. Average48% Short Selling Akebia Therapeutics ? Sign up to receive the latest short interest report for Akebia Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatAKBA Short Interest Over TimeAKBA Days to Cover Over TimeAKBA Percentage of Float Shorted Over Time Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" Akebia Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/202413,400,000 shares $24.52 million +32.3%N/A3 $1.83 3/15/202410,130,000 shares $17.22 million +24.9%N/A3.4 $1.70 2/29/20248,110,000 shares $12.81 million +1.4%N/A4 $1.58 2/15/20248,000,000 shares $11.76 million -8.9%N/A4.5 $1.47 1/31/20248,780,000 shares $14.75 million +12.1%N/A5.4 $1.68 1/15/20247,830,000 shares $12.14 million -0.5%N/A5 $1.55 Get the Latest News and Ratings for AKBA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/20237,870,000 shares $9.76 million +7.4%N/A5.3 $1.24 12/15/20237,330,000 shares $8.43 million -18.7%N/A5.5 $1.15 11/30/20239,010,000 shares $9.55 million -8.8%N/A6.9 $1.06 11/15/20239,880,000 shares $9.88 million -4.3%N/A6.8 $1.00 10/31/202310,320,000 shares $9.08 million +33.2%N/A6.8 $0.88 10/15/20237,750,000 shares $7.03 million +6.5%N/A4.5 $0.91 9/30/20237,280,000 shares $8.30 million +0.7%N/A4.4 $1.14 9/15/20237,230,000 shares $9.11 million +24.4%N/A4.1 $1.26 8/31/20235,810,000 shares $8.08 million -14.1%N/A3.1 $1.39 8/15/20236,760,000 shares $8.86 million +10.3%N/A3.2 $1.31 7/31/20236,130,000 shares $10.24 million +13.7%N/A2.8 $1.67 7/15/20235,390,000 shares $5.71 million +11.4%N/A2.9 $1.06 6/30/20234,840,000 shares $4.43 million +11.3%N/A2.7 $0.92 6/15/20234,350,000 shares $4.96 million -15.5%N/A2.5 $1.14 5/31/20235,150,000 shares $5.36 million +26.5%N/A3 $1.04 5/15/20234,070,000 shares $4.44 million -9.6%N/A2.4 $1.09 4/30/20234,500,000 shares $4.09 million -20.8%N/A2.4 $0.91 4/15/20235,680,000 shares $3.57 million +0.4%N/A2.9 $0.63 3/31/20235,660,000 shares $3.17 million -15.3%N/A2.8 $0.56 3/15/20236,680,000 shares $4.49 million -20.3%N/A3 $0.67 2/28/20238,380,000 shares $7.06 million +82.6%N/A3.5 $0.84 2/15/20234,590,000 shares $4.07 million +38.3%N/A2 $0.89 1/31/20233,320,000 shares $2.09 million -28.1%N/A1.7 $0.63 1/15/20234,620,000 shares $3.21 million -0.9%N/A2.7 $0.70 12/30/20224,660,000 shares $2.69 million -0.4%N/A2.7 $0.58 12/15/20224,680,000 shares $2.12 million -2.9%N/A3.1 $0.45 11/30/20224,820,000 shares $1.30 million -12.5%N/A3.4 $0.27 11/15/20225,510,000 shares $1.41 million -6.9%N/A3.8 $0.26 10/31/20225,920,000 shares $1.51 million -5.9%N/A3.4 $0.25 10/15/20226,290,000 shares $1.82 million -13.4%N/A2.7 $0.29 9/30/20227,260,000 shares $2.30 million -5.8%N/A2.6 $0.32 9/15/20227,710,000 shares $2.85 million -3.5%N/A1.1 $0.37 8/31/20227,990,000 shares $2.91 million -14.5%N/A1 $0.36 8/15/20229,340,000 shares $3.87 million -18.5%N/A1 $0.41Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now AKBA Short Interest - Frequently Asked Questions What is Akebia Therapeutics' current short interest? Short interest is the volume of Akebia Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 31st, investors have sold 13,400,000 shares of AKBA short. Learn More on Akebia Therapeutics' current short interest. What is a good short interest ratio for Akebia Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. AKBA shares currently have a short interest ratio of 3.0. Learn More on Akebia Therapeutics's short interest ratio. Which institutional investors are shorting Akebia Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Akebia Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Akebia Therapeutics' short interest increasing or decreasing? Akebia Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 13,400,000 shares, an increase of 32.3% from the previous total of 10,130,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Akebia Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Akebia Therapeutics: Erasca, Inc. (9.88%), CorMedix Inc. (15.05%), Verrica Pharmaceuticals Inc. (16.52%), Inozyme Pharma, Inc. (6.27%), Terns Pharmaceuticals, Inc. (10.92%), XOMA Co. (2.36%), RAPT Therapeutics, Inc. (8.56%), Aquestive Therapeutics, Inc. (3.10%), Kamada Ltd. (0.13%), Verastem, Inc. (3.10%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks. What does it mean to sell short Akebia Therapeutics stock? Short selling AKBA is an investing strategy that aims to generate trading profit from Akebia Therapeutics as its price is falling. AKBA shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Akebia Therapeutics? A short squeeze for Akebia Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of AKBA, which in turn drives the price of the stock up even further. How often is Akebia Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AKBA, twice per month. The most recent reporting period available is March, 31 2024. More Short Interest Resources from MarketBeat Related Companies: ERAS Short Interest Data CRMD Short Interest Data VRCA Short Interest Data INZY Short Interest Data TERN Short Interest Data XOMA Short Interest Data RAPT Short Interest Data AQST Short Interest Data KMDA Short Interest Data VSTM Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AKBA) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press